Rebecca Storey and Shazia Ahmed, our senior and junior trials coordinators respectively, have been busy writing all the regulatory documents needed for the trial to go ahead. These were submitted to the Health Regulatory Authority in early January. The ethics committee met in early February. This was in Glasgow, but we were allowed to join by telephone conference. the committee was very sympathetic and had only minor requests. Rebecca and I are writing the response, which has to be back with them by Wed. We cannot get complete regulatory sign-off until we have evidence that the study medicine is stable outside it’s manufacturer’s packaging.

Regarding the study medicine, we have been in weekly contact with the pharmacy manufacturing unit at Guy’s and Thomas’s Hospital in London. They have outsourced the testing of the medicine to a commercial contract company, Butterworth’s. So, the problem is that the study medicine comes in foil blister packs. The manufacturer only guarantees the quality of the tablets while they are in their own packaging. For the clinical trial, Guy’s and Thomas’s Pharmacy have to take the tablets out of the manufacturer’s packaging and put them into white polypropylene containers, so that they can be masked (blinded) with the placebo tablets. Unfortunately, these study tablets absorb moisture from the atmosphere when taken out of their foil packaging, which in theory may affect the stability of the active component. Guy’s and Thomas’s hospital have been trying to test some tablets that they have kept in typical study bottles; but without success. They then outsourced this job to Butterworth’s, who found a non-standard method to measure drug stability. However, when they tried to convert this to an approved method, they could not get the measurements to work. This is turning into a major headache, and is the reason the study has been held up. We are having a telephone conference on Monday with the pharmacy team to get an update and plan what we do next.

We have appointed a new study team member, Heather Rose, who will look after the MRI scans for the trial, and do the measurements to see if the study drug is slowing down the brain changes. She is getting the scanners set up in Birmingham for both children and adults to take part.

Rebecca has been in touch with the international sites, in Almeria, Montpellier, Paris and Lodz, to start getting them set up.

Finally, I have been asked to speak with the French families in Paris on March 17th to explain to them where the trial is at.

Dear Friends,Fumihiko “Fumi” Urano, MD

Thank you so much for “coming to see me” today. It is always my pleasure and privilege to see you and talk to you. I feel your support and encouragement, and I am grateful for everything you have done for me, the Snow Foundation, patients, and their families and friends. Just reading this blog is helping me because I can feel your support, which makes me feel stronger and committed.

I would like to share my ideas on how to provide a cure for Wolfram with you today as our first clinical trial is ongoing and we are making steady progress in the development of new drugs, regenerative therapy, and gene therapy. I have been thinking and presenting my strategy for therapeutic development of Wolfram syndrome, CURE4WOLFRAM, since 2002. My current version, 4.0, is the following.

1. Stop Progression

ER Calcium Stabilizers
One of the common molecular pathways altered in patients with Wolfram syndrome and diabetes patients is imbalanced cellular calcium homeostasis. More specifically, endoplasmic reticulum (ER) calcium levels are lower in patients with Wolfram syndrome, leading to cell dysfunction and death. To overcome this challenge, we are currently testing if an ER calcium stabilizer, dantrolene sodium, can delay the progression of Wolfram syndrome. Dantrolene sodium is a FDA-approved drug for the treatment of muscle spasticity and high fever induced by anesthesia. We previously reported that dantrolene sodium stabilizes ER calcium levels and prevents cell death in cell and mouse models of Wolfram syndrome. We are currently conducting a clinical trial of dantrolene sodium in adult and pediatric patients with Wolfram syndrome. In collaboration with NIH/NCATS, we are also developing novel ER calcium stabilizers (i.e., second generation dantrolene) for the treatment of Wolfram syndrome.

Molecular Prosthetics
Another common issue in patients with Wolfram syndrome is ER stress caused by the expression of mutant Wolfram protein produced in patients’ cells. To resolve this issue, we have been developing molecular prosthetics that can optimize the structure of mutant Wolfram protein together with NIH/NCATS and Amylyx, a biotech company in Cambridge, MA.

2. Protect and Regrow Remaining Tissue

Our second step towards a cure for Wolfram syndrome is to protect and regrow remaining tissue using regenerative therapy. We have discovered a naturally produced molecule in our body that can activate the proliferation of damaged beta cells and brain cells. Expression levels of this molecule, MANF, are usually low in our body. We are developing a method to enhance the activity of MANF using a pill that can mimic the functions of MANF and gene therapy (i.e., produce safe virus expressing MANF).

3. Replace Pathogenic Genes

Towards a cure for Wolfram syndrome, a genetic condition, we need to target the root cause of the disease, which is the loss of function of Wolfram syndrome gene, WFS1. Using CRISPR/CAS9 technology, we are attempting to replace a pathogenic Wolfram gene (WFS1 gene) with a healthy Wolfram gene. We are also trying to introduce safe virus expressing normal WFS1 gene into patients’ cells.

Thank you so much for being with me today. Good things happen to people who do good things. I am always hopeful.

With grace and gratitude,
Fumi Urano